About Cardax

Cardax is a development stage biopharmaceutical company primarily focused on the development of pharmaceuticals for chronic diseases driven by inflammation. CDX-101, our astaxanthin pharmaceutical candidate, is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, our zeaxanthin pharmaceutical candidate, is being developed for macular degeneration, with a target initial indication of Stargardt disease. Our pharmaceutical candidates are currently in pre-clinical development, including the planning of IND enabling studies. We also have a commercial business unit that markets ZanthoSyn®, a physician recommended astaxanthin dietary supplement for inflammatory health. We sell ZanthoSyn® primarily through wholesale and e-commerce channels.

Learn more >>

About Astaxanthin

Astaxanthin is a powerful and safe naturally occurring anti-inflammatory without the side effects of currently marketed anti-inflammatories.

Learn about astaxanthin >>

Commercialization Strategy

We believe we are well positioned for significant and sustained growth by developing and commercializing safe anti-inflammatory dietary supplements and drugs that address large unmet needs.

Learn more about our commercialization strategy >>

Intellectual Property Portfolio

We have 29 issued patents and one pending patent related to the composition of matter, pharmaceutical compositions, and pharmaceutical uses of our drug candidates as well as many other related molecules that will expire between 2023 and 2028, subject to patent term extensions. We also have filed additional patents to extend patent coverage in the U.S. and worldwide to 2039-2040, with such applications including coverage related to certain cardiovascular uses on the basis of the CHASE clinical trial results as well as coverage related to the composition of matter of CDX-101.

View our patent holdings >>

The Cardax Team

Cardax is led by a highly experienced management team, board of directors, and scientific advisory board.

Meet our management team >>